SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:82e190ae-d8ba-4d11-9891-0a07d4279f50"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:82e190ae-d8ba-4d11-9891-0a07d4279f50" > CRP, C-Peptide, and...

  • Gedebjerg, AnneAarhus University Hospital (författare)

CRP, C-Peptide, and Risk of First-Time Cardiovascular Events and Mortality in Early Type 2 Diabetes : A Danish Cohort Study

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • 2023-03-17
  • American Diabetes Association,2023
  • 9 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:82e190ae-d8ba-4d11-9891-0a07d4279f50
  • https://lup.lub.lu.se/record/82e190ae-d8ba-4d11-9891-0a07d4279f50URI
  • https://doi.org/10.2337/dc22-1353DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • We investigated the relationship between hs-CRP, a marker of low-grade inflam-mation, alone or in combination with C-peptide, a marker of hyperinsulinemia/ insulin resistance, and risk for cardiovascular events (CVEs) and mortality in patients recently diagnosed with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS In patients with recent-onset T2D, we measured serum hs-CRP (n = 7,301) and C-peptide (n = 5,765) in the prospective Danish Centre for Strategic Research in Type 2 Diabetes cohort study. Patients with no prior CVE (n = 6,407) were followed until first myocardial infarction, stroke, coronary revascularization, or cardiovascular death, and all patients (n = 7,301) were followed for all-cause mortality. We com-puted adjusted hazard ratios (aHRs) by Cox regression and tested for the interaction between hs-CRP and C-peptide. RESULTS During follow-up (median 4.8 years), high (>3 mg/L) versus low (<1 mg/L) hs-CRP was associated with increased CVE risk (aHR 1.45 [95% CI 1.07–1.96]) and with even greater risk of all-cause mortality (2.47 [1.88–3.25]). Compared with patients with low hs-CRP (£3 mg/L) and low C-peptide (<1,470 pmol/L), those with high lev-els of both biomarkers had the highest CVE (1.61 [1.10–2.34]) and all-cause mortality risk (2.36 [1.73–3.21]). Among patients with high C-peptide, risk of CVEs did not differ by low or high hs-CRP, whereas risk of all-cause mortality did. CONCLUSIONS The finding of high hs-CRP as a stronger prognostic biomarker of all-cause mortality than of CVEs may facilitate improved early detection and prevention of deadly diseases besides CVEs. Conversely, elevated C-peptide as a strong CVE biomarker sup-ports the need to target hyperinsulinemia/insulin resistance in T2D CVE prevention.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bjerre, MetteAarhus University (författare)
  • Kjaergaard, Alisa DevedzicAarhus University Hospital (författare)
  • Nielsen, Jens SteenOdense University Hospital (författare)
  • Rungby, JørgenSteno Diabetes Center Copenhagen,Bispebjerg Hospital (författare)
  • Brandslund, IvanVejle Hospital (författare)
  • Maeng, MichaelAarhus University Hospital (författare)
  • Beck-Nielsen, HenningOdense University Hospital (författare)
  • Vaag, AllanLund University,Lunds universitet,Translationell diabetesforskning,Forskargrupper vid Lunds universitet,Translational Diabetes Research,Lund University Research Groups,Steno Diabetes Center Copenhagen(Swepub:lu)med-ava (författare)
  • Sørensen, Henrik ToftAarhus University Hospital (författare)
  • Hansen, Troels KrarupAarhus University Hospital (författare)
  • Thomsen, Reimar WernichAarhus University Hospital (författare)
  • Aarhus University HospitalAarhus University (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Diabetes Care: American Diabetes Association46:5, s. 1037-10450149-59921935-5548

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy